Skip to main content

Chacko Jacob's Form 4 filing

Oric Pharmaceuticals, Inc. (ORIC) · filed Dec 17, 2024

Accession no.
0001415889-24-029631
Filed
Dec 17, 2024
Trade date
Dec 15-16, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $204.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Chacko JacobCIK 0001608936Director, Officer (PRESIDENT AND CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 15, 2024Common StockMOption exerciseAcquired+67,000$0.00F1$0803,308Direct
Dec 16, 2024Common StockSSaleDisposed−24,660$8.28F4−$204,184.8778,648Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 15, 2024Common StockMOption exerciseDisposed−16,667$0.00$00Direct
Dec 15, 2024Common StockMOption exerciseDisposed−22,000$0.00$022,000Direct
Dec 15, 2024Common StockMOption exerciseDisposed−28,333$0.00$056,667Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

Referenced by the price of 1 transaction in Table I.

F4

Represents the weighted average share price of an aggregate total of 24,660 shares sold in the price range of $8.27 to $8.39 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)